Robert Stagg
0009-0009-3797-0151
Tempest Technologies (United States)
1 paper found
Refreshing results…
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Missing publications? Search for publications with a matching author name.